Table 1

Patient characteristics. AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HL, Hodgkin’s lymphoma; ALL, acute lymphoblastic leukemia; MDS, myelodyplastic syndrome; NHL, non-Hodgkin’s lymphoma; PBSCs, peripheral blood stem cells; BM, bone marrow; MMF, mycophenolate mofetil.

Cohort 1Cohort 2
No chronic
GVHD
(n = 14)
Chronic
GVHD
(n = 31)
PIL-2–treated
chronic
GVHD
(n = 14)
n%n%n%
Age at SCT, median
(range)
44 (27–52)48 (20–63)0.31
M/F10/419/120.065/9
Diagnosis0.59
  AML642.91548.4535.7
  CLL17.1412.9535.7
  CML214.3412.917.1
  HL0013.217.1
  ALL321.426.5
  MDS0039.717.1
  NHL214.326.517.1
Conditioning
regimen
0.3
  Myeloablative141002683.9750
  Nonmyeloablative00516.1750
Stem cell source1
  PBSCs141003096.81392.9
  BM and PBSCs0013.217.1
Donor type0.04
  Matched-related1285.71445.2428.6
  Matched-unrelated214.31445.2750
  Mismatched-
unrelated
0039.7321.4
  Acute GVHD
prophylaxis
0.33
  Sirolimus-
containing
1071.41651.6964.3
  No sirolimus-
containing
428.61548.4535.7
Acute GVHD0.02
  Grade 2–417.11445.2535.7
Days to sample
collection
  Median216810200.1
  Range440–2952412–2807
Days to
chronic GVHD
  Median (range)263 (125–927)269 (130–483)
Severity of
chronic GVHD
  Mild929
  Moderate825.8
  Severe1445.2
Immunosuppressive
therapy*
  Prednisone0.0001
    0 mg1285.7619.417.1
    0 to ≤10 mg214.31032.3214.2
    >10 mg00.01548.41178.6
  Sirolimus0.09
    0 mg1392.91961.3871
    0 to ≤1 mg17.1722.6214.2
    >1 mg00.0516.1428.4
  Tacrolimus0.04
    0 mg14100.02064.5964.3
    0 to ≤1 mg00.0619.4214.2
    >1 mg00.0516.1321.3
  MMF0.007
    0 mg14100.01651.6428.4
    0 to ≤500 mg00.039.717.1
    >500 mg00.01238.7964.3

*In cohort 1 patients, immunosuppressive therapies when samples were collected are shown. In cohort 2 patients, immunosuppressive therapies at the initiation of low-dose IL-2 therapy are shown.